Finding 57887 (2022-001)

Material Weakness Repeat Finding
Requirement
A
Questioned Costs
-
Year
2022
Accepted
2023-09-28
Audit: 54355

AI Summary

  • Core Issue: The Company failed to keep necessary audit evidence for report logic used to identify eligible patients for COVID-19 testing reimbursement, leading to potential inaccuracies.
  • Impacted Requirements: Lack of effective internal controls over report writing and user access, violating Section 200.303 of the Uniform Guidance.
  • Recommended Follow-Up: Retain evidence of internal controls and implement a monthly quality review process for claims to ensure ongoing compliance if the program is reinstated.

Finding Text

Finding 2022-001 Activities Allowed or Unallowed and Eligibility, Information on the federal program: Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA) Assistance Listing No.: 93.461, COVID-19 Testing for the Uninsured Pass-Through Award Period of Performance: 01/01/2022-03/31/2022; Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): Section 200.303 of the Uniform Guidance states the following regarding internal control: ?The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in ?Standards for Internal Control in the Federal Government? issued by the Comptroller General of the United States or the ?Internal Control Integrated Framework?, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).? Condition: The Company did not retain audit evidence to support the report logic that was developed to extract patients from the patient billing systems that were identified as having an allowable COVID-19 testing and treatment diagnosis code with uninsured eligibility determination and eligible for reimbursement under this federal program. In addition, supporting documentation was not retained to validate who had access to modify and run the script, what changes were made to the script and how any changes to the script were tested and implemented during the fiscal year based on changes to HRSA guidance and how management validated the completeness and accuracy of the data extracted by the script. Cause: The Revenue Cycle department did not develop and maintain effective internal control over report writing, program changes and user access. In addition, while management represented that the report logic and subsequent changes to the report logic were reviewed, no audit evidence was retained to support that process. Questioned costs: None. Context: Total federal expenditures for Assistance Listing 93.461 totaled $1,214,572 for the year ended December 31, 2022. Effect or potential effect: The key report used to identify eligible federal program participants could be inaccurate or incomplete. Identification as a repeat finding, if applicable: The finding is a repeat of finding 2021-004 from the prior year. Recommendation: Although the program has now ended, the Company should retain evidence of internal controls related to access and change management over the report should the program be reinstated. Additionally, management should implement a quality review process of eligible claims identified on a monthly basis to ensure that patients identified meet the required eligibility requirements. Views of Responsible Officials: As part of the prior year audit finding, the Company implemented a process as of January 2022 to document internal controls related to the quality review of claims to ensure patients meet the eligibility requirements. HRSA reviewed the documentation and determined that the finding had been satisfactorily resolved. Although the program has now ended, the Company will ensure the internal controls are documented should the HRSA program be reinstated.

Corrective Action Plan

Corrective Action Plan Finding 2022-001 Assistance Listing #93.461 Internal Control over Compliance? Activities Allowed or Unallowed and Eligibility, Due to the evolving nature of the COVID-19 pandemic, and the rapid pace in which programs were implemented, documentation of controls related to the reporting of COVID-19 uninsured patients was not maintained. However, controls were in place and proper submission of claims was accurate. As part of the prior year audit finding, NorthShore implemented a process as of January 2022 to document internal controls related to the quality review of claims to ensure patients meet the eligibility requirements. HRSA reviewed the documentation and determined that the finding had been satisfactorily resolved. Although the program has now ended, NorthShore will ensure the internal controls are documented should the HRSA program be reinstated. Responsible Official: John Skeans, Senior Vice President, Patient Financial Services.

Categories

Cash Management Eligibility Period of Performance Matching / Level of Effort / Earmarking Internal Control / Segregation of Duties

Other Findings in this Audit

  • 634329 2022-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.461 Covid-19 Testing for the Uninsured $1.21M
93.866 Aging Research $1.06M
93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $600,665
93.074 Hospital Preparedness Program (hpp) and Public Health Emergency Preparedness (phep) Aligned Cooperative Agreements $487,207
93.310 Trans-Nih Research Support $461,727
93.391 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crises $445,560
93.268 Immunization Cooperative Agreements $366,906
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $359,297
93.242 Mental Health Research Grants $293,207
93.350 National Center for Advancing Translational Sciences $286,340
93.307 Minority Health and Health Disparities Research $221,355
93.226 Research on Healthcare Costs, Quality and Outcomes $215,268
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $120,106
21.027 Coronavirus State and Local Fiscal Recovery Funds $115,788
93.994 Maternal and Child Health Services Block Grant to the States $92,631
93.865 Child Health and Human Development Extramural Research $61,608
93.837 Cardiovascular Diseases Research $53,475
93.855 Allergy, Immunology and Transplantation Research $53,093
14.218 Community Development Block Grants/entitlement Grants $45,000
93.859 Biomedical Research and Research Training $39,688
93.172 Human Genome Research $37,305
93.124 Nurse Anesthetist Traineeships $36,712
12.420 Military Medical Research and Development $34,901
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $30,901
93.397 Cancer Centers Support Grants $23,936
93.667 Social Services Block Grant $17,400
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $16,542
93.273 Alcohol Research Programs $15,039
93.838 Lung Diseases Research $12,192
93.396 Cancer Biology Research $11,886
93.394 Cancer Detection and Diagnosis Research $11,337
93.110 Maternal and Child Health Federal Consolidated Programs $10,972
93.361 Nursing Research $6,984
93.839 Blood Diseases and Resources Research $6,874
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $6,288
93.393 Cancer Cause and Prevention Research $4,578
93.395 Cancer Treatment Research $50